Atossa Therapeutics Inc
ATOS
Company Profile
Business description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Contact
1448 NW Market Street
Suite 500
SeattleWA98107
USAT: +1 206 588-0256
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
This former ASX tech darling is now 25% undervalued
Shares have fallen over 40% this year but revenue is still growing quickly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,267.80 | 104.40 | 1.14% |
| CAC 40 | 8,278.59 | 45.30 | 0.55% |
| DAX 40 | 26,347.45 | 80.26 | 0.31% |
| Dow JONES (US) | 52,231.89 | 157.86 | -0.30% |
| FTSE 100 | 10,751.59 | 31.28 | -0.29% |
| HKSE | 24,557.04 | 108.09 | 0.44% |
| NASDAQ | 25,065.87 | 187.27 | -0.74% |
| Nikkei 225 | 60,459.58 | 1,684.08 | 2.87% |
| NZX 50 Index | 14,086.34 | 81.07 | -0.57% |
| S&P 500 | 7,520.93 | 29.01 | -0.38% |
| S&P/ASX 200 | 9,129.00 | 99.30 | 1.10% |
| SSE Composite Index | 3,663.72 | 2.93 | 0.08% |